In This Article:
Organogenesis Holdings (NASDAQ:ORGO) Full Year 2024 Results
Key Financial Results
-
Revenue: US$482.0m (up 11% from FY 2023).
-
Net loss: US$937.0k (down by 119% from US$4.95m profit in FY 2023).
-
US$0.007 loss per share (down from US$0.038 profit in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Organogenesis Holdings Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 3.5%. Earnings per share (EPS) also surpassed analyst estimates by 85%.
Looking ahead, revenue is forecast to grow 2.7% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 93% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 2 warning signs for Organogenesis Holdings (1 is potentially serious!) that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.